← All trials
NCT05761041
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 28, 2022
- Primary completion
- Mar 30, 2023
- Completion date
- Apr 15, 2023
- First posted
- Mar 9, 2023
- Last posted
- Jul 20, 2023
- Enrollment
- 140
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Alexandria UniversityLead sponsor
- Alexandria UniversityReponsible party - principal investigator
- Alexandria UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.